Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07094516 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT07094516 is a Phase 2 study of Alzheimers Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 407 participants, below the 4,058-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT07094516, a Phase 2 study of Alzheimers Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL VHB937
Study Locations (20)
Florida
- Jem Research Institute - Atlantis
- Visionary Investigators Network - Aventura
- K2 Medical Research LLC - Maitland
- K2 Medical Research LLC - Maitland
- Renstar Medical Research - Ocala
- Charter Research The Villages - The Villages
- Alzheimers Research Treatment Ctr - Wellington
- Alzheimers Research Treatment Ctr - Wellington
- Conquest Research - Winter Park
California
- University of California San Diego - La Jolla
- University of California at Los Angeles - Los Angeles
Arizona
- Banner Alzheimers Institute - Phoenix
Hawaii
- Hawaii Pacific Neuroscience LLC - Honolulu
Kansas
- University of Kansas Hospital - Fairway
Massachusetts
- ActivMed Practices and Research - Methuen
Missouri
- Citizens Memorial Hospital Neurology CLinic - Bolivar
North Carolina
- UNC Hosp Invest Drug Serv Pharm - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07094516
The ClinicalTrials.gov registry entry for NCT07094516 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,058-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (90% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07094516 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07094516 about?
NCT07094516 is a clinical study titled "A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease". This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
What is the current status of trial NCT07094516?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 407 participants. The study started on 2025-08-07. Estimated completion is 2030-12-31.
What conditions does trial NCT07094516 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07094516?
The interventions under investigation include: Placebo (OTHER), VHB937 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07094516?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07094516 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Hawaii, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.